Substance / Medication

Teniposide

SNOMED 387460005 UMLS C0039512

Overview

Active Ingredient

teniposide

RxNorm CUI

10362

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Neoplasm of lung

Lymphatic leukaemia

Small cell carcinoma

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)

NCT00361140Phase 4Completed72 enrolled

ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)

NCT02670564Phase 4Recruiting1000 enrolled

View all 2 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

[Radiotherapy of malignant brain gliomas using teniposide].

Mufazalov F F, Sakaeva D D, Shtefan A Iu · Vopr Onkol · 2008

PMID: 18522171RCT

First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study.

Zhong Kaili, Shi Yanyan, Gao Yuhuan et al. · BMC Cancer · 2023

PMID: 37568079ObservationalFull text (PMC)

Preparation and evaluation of teniposide-loaded polymeric micelles for breast cancer therapy.

Chu Bingyang, Shi Shuai, Li Xingyi et al. · Int J Pharm · 2016

PMID: 27596115Observational

Fotemustine, teniposide and dexamethasone in treating patients with CNS lymphoma.

Wu Jing-Jing, Wang Xin-Hua, Li Ling et al. · Asian Pac J Cancer Prev · 2014

PMID: 24969912Observational

The addition of ifosfamide/etoposide to cisplatin/teniposide improves the survival of children with retinoblastoma and orbital involvement.

Antoneli Célia Beatriz Gianotti, Ribeiro Karina B, Rodriguez-Galindo Carlos et al. · J Pediatr Hematol Oncol · 2007

PMID: 17921851Observational

Evaluation of teniposide (VM-26)-induced toxicity on mouse spermatogenesis by flow cytometry.

Jyothi P, Jagetia G C, Krishnamurthy H · Toxicology · 2001

PMID: 11516526Observational

STING activation by teniposide: a potential direct mechanism beyond cGAS stimulation.

Arranz-Herrero Javier, Marquez-Cantudo Laura, Rius-Rocabert Sergio et al. · Front Immunol · 2025

PMID: 41550929OtherFull text (PMC)

Teniposide Triggers DNA Repair Inhibition by Binding and Ubiquitination of Apurinic/Apyrimidinic Endonuclease 1 to Boost Oxidative DNA Damage for Lung Cancer Destruction.

Han Ning, Hu Jun, Xie Zhong-Xiong et al. · ACS Pharmacol Transl Sci · 2025

PMID: 40810145OtherFull text (PMC)

Multimodal treatment with thiotepa, bevacizumab, teniposide, and tunlametinib in a patient with neurofibromatosis type 1-associated oligodendroglioma: a rare case report.

Zhou Shizhen, Chen Yanfei, Gao Guoliang et al. · Anticancer Drugs · 2025

PMID: 41176787Other

Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study.

Bromberg Jacoline E C, Issa Samar, van der Holt Bronno et al. · Neuro Oncol · 2024

PMID: 38037691TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Teniposide (substance)
SNOMED CT: 387460005
UMLS CUI: C0039512
RxNorm CUI: 10362

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.